PLK1 and lung cancer: Selective Polo-like kinase 1 Polo-Box Domain (PLK1 PBD) inhibitor MCC1019 (compound 2) (see Figure 2) is a bromomethyl-substituted benzofuran developed by Abdelfatah and colleagues for the treatment of lung cancer and evaluated via in silico, in vitro, and in vivo models [33].